ImmunoGen, Inc. Hires Craig Barrows as Vice President, General Counsel and Secretary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that Craig Barrows has joined the Company as Vice President, General Counsel and Secretary. Mr. Barrows has over twenty years of legal experience - thirteen as chief corporate legal officer - and a strong transactional background. This newly-created position reflects the Company's increased involvement with multiple current and potential collaborators, medical institutions, and commercial manufacturing organizations as a growing number of TAP compounds advance.
"We're delighted to have Craig at ImmunoGen," commented Mitchel Sayare, Chairman and CEO. "He has a solid background in business, corporate and securities law gained as senior in-house counsel and at a leading national law firm, and is comfortable working in a lean organization. Of particular interest is Craig's experience in the development of contracts with a wide range of partners, suppliers, and other third parties, as our needs in this area have increased substantially with our expanding collaborations and the advancement of TAP compounds."
Mr. Barrows has extensive experience as the chief legal officer of publicly-traded companies. He was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Most recently, Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. ImmunoGen's proprietary TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds, two of which are TAP compounds, are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1 (T-DM1), in development by Genentech. Multiple compounds are in research/preclinical development.
CONTACT:
Investors
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
Media:
KMorrisPR
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com
